

**GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG
DISEASE(GOLD)
DISCLOSURE OF FINANCIAL INTEREST
January 1, 2019-December 31, 2019**



Background

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program is a collaboration between the scientific community and the private sector. The major objectives are: (1) to increase awareness of Chronic Obstructive Lung Disease among health professionals, health authorities, and the general public; (2) improve diagnosis, management, and prevention; and (3) stimulate research. These objectives are being met through preparation of scientific reports on Chronic Obstructive Lung Disease, dissemination and adoption of recommendations in these reports, and promotion of international collaboration on Chronic Obstructive Lung Disease research.

The purpose of this document is to safeguard the interests of all GOLD collaborators by an open disclosure of interests.

GOLD Structure

At present, the GOLD program is conducted through a GOLD Board of Directors that meets annually (usually in January), a Scientific Committee and a Dissemination Committee. Each Committee will have an active role in reviewing and recommending content for GOLD documents and all members will be asked to complete this form.

Annual Declaration of Interests

The following declarations are requested by GOLD. Please complete the company name select in the corresponding box whether you have financial relationships (received grants, personal fees, shares, non-financial support, other). Please include all companies in the bio-medical arena, as well as telehealth/technology, and tobacco entities. This form will be posted on the GOLD website after completion.

Definitions:

- 1. Grants :** refers to any grant paid to your organization.
- 2. Personal Fees:** refers to honorarium, consultation fees, etc for lectures, advisory committees or consultancy services either intermittent or regular, from

which a GOLD member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.

3. *Shares:* refers to any shares in Chronic Obstructive Lung Disease-related commercial organizations, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GOLD member or family members (spouse/children). The company is to be listed, not the number of shares.

4. *Non-financial support:* In-kind assistance.

The private sector should not in any way be involved in any aspect of developing documents, including collecting, reviewing or accessing the literature or determining the content. Once documents have been produced Chronic Obstructive Lung Disease-related commercial organizations can be involved in their dissemination and audit, including support for publications.

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Aquiles Camelier – City of Salvador, Brazil

Member of: Brazil National leader

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Boehringer - Ingelheim	No	Yes	Yes	No	Intermittent personal fees for lectures, advisory committees and financial support to attend to scientific meetings
Chiesi	No	Yes	No	No	Intermittent personal fees for lectures, advisory committees and financial support to attend to scientific meetings
Glenmark	No	Yes	No	No	Intermittent personal fees for lectures.

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Corlateanu Alexandru

Member of: GOLD National Leader for Moldova
Member of GINA Assembly for Moldova

Are there any relevant financial interests to disclose? (Yes or No in each box)

I am declaring no conflict of interest.

25 February 2020

Alexandru Corlateanu, MD, PhD
Associate Professor, Department of Respiratory Medicine,
Deputy Chief of Research Department on International Relations,
State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Moldova
Email alexandru.corlateanu@usmf.md
Mobile +37379571600

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Stanislav Kos M.D., PhD.

Member of: Czech Civic Association Against Lung Diseases

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Novartis	Yes	No	No	No	
Roche	Yes	No	No	No	
Takeda	Yes	No	No	No	
AstraZeneca	Yes	No	No	No	
CSL Behring	Yes	No	No	No	
S+D Pharma CZ	Yes	No	No	No	
Sandoz	Yes	No	No	No	
Angelini	Yes	Yes	No	No	consultations
Boehringer Ingelheim	Yes	No	No	No	
Chiesi	Yes	No	No	No	
Berlin-Chemie Menarini	Yes	No	No	No	
Linde	Yes	No	No	No	
Saegeling Medizintechnik	Yes	No	No	No	
ResMed	Yes	No	No	No	
Medial	Yes	No	No	No	

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Le Thi Tuyet Lan

Member of: University Medical Center HCMC

Are there any relevant financial interests to disclose?: No

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
NA	NA	NA	NA	NA	NA

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Damilya Nugmanova

Member of: GOLD Assembly representing Kazakhstan

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
	No	No	No	No	

In year 2019 I didn't receive any grants, personal fees, shares, non-financial support from COPD-related commercial organizations

Damilya Nugmanova

January, 30, 2020
Almaty, Kazakhstan

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Yeon-Mok Oh

Member of: the GOLD National Leaders

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
GSK KOREA	Yes	Yes	No	No	grants for clinical studies and honoraria for lectures
MSD Korea	No	Yes	No	No	honorarium
Norvatis Korea	No	Yes	No	No	transportation
AstraZeneca Korea	No	Yes	No	No	honorarium
ChongGunDang	Yes	No	No	No	a grant for animal study
Boehringer Ingelheim Korea	Yes	No	No	No	grants for clinical studies
Sanofi-Aventis Korea	Yes	No	No	No	a grant for clinical study
Parexel Korea	Yes	No	No	No	a grant for clinical study

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Ruxandra Ulmeanu

Member of: Romanian Society of Pneumology

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
GlaxoSmith&Kline	Yes				
Parexel	Yes				
Mundipharma	Yes				
Chiesi Romania	Yes			Consultation fees Congresses fees	
Novartis Pharma Services Romania	Yes			Consultation fees Congresses fees	
Bayer	Yes				
Aradigm	Yes				
Sanofi	Yes				
Ab Science	Yes				
Angelini Pharmaceuticals				Consultation fees Congresses fees	
Astrazeneca Pharma				Consultation fees Congresses fees	
Boehringer Ingelheim				Consultation fees Congresses fees	
Servier Pharma				Consultation fees Congresses fees	
MSD Romania				Congresses fees	
Roche Romania				Congresses fees	

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Richard van Zyl-Smit

Member of: South African Thoracic Society

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Astra Zeneca		Yes			
Cipla		yes			
Novartis		yes			
Pfizer		yes			
Roche		yes			
MSD		yes			
ASPEN/GSK		yes			
Janssen		yes			
Adcock Ingram		yes			

